Trevena to Participate in Upcoming Conferences in June 2019

CHESTERBROOK, Pa., May 29, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients affected by Central Nervous System conditions, today announced that Carrie Bourdow, President and Chief Executive Officer, and Mark Demitrack, SVP and Chief Medical Officer, will present at two upcoming conferences:

• 2019 BIO International Convention, sponsored by the Biotechnology Innovation Organization, to be held at the Philadelphia Convention Center in Philadelphia, PA on Wednesday, June 5, 2019 at 3:45pm ET. Live audio webcast and archived replay of the presentation will be available on the Company’s investor relations website at https://investors.trevena.com/. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
• JMP Securities Life Sciences Conference, sponsored by JMP Securities, to be held at The St. Regis New York in New York City on June 20, 2019 at 1:30pm ET.

For more information about the conferences, or to schedule a one-on-one meeting with the Company’s management, please contact KCSA Strategic Communications at [email protected], or send an email to [email protected] (2019 BIO International Convention), or [email protected] (JMP Securities Life Sciences Conference). 

About TrevenaTrevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients affected by Central Nervous System conditions.  The Company has four novel and differentiated investigational drug candidates, including IV oliceridine, for the management of moderate to severe acute pain in hospitals, TRV250 for the acute treatment of migraine, and TRV734 for maintenance treatment of opioid use disorder.  The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to managing chronic pain.

For more information, please contact:

Investor Contact:Valter Pinto / Allison SossKCSA Strategic CommunicationsPhone: 212-896-1254 / 212-896-1267Email: [email protected]  

Company Contact:Bob Yoder, SVP and Chief Business OfficerTrevena, Inc.Phone: 610-354-8840

You May Also Be Interested In

• Katten Expands Restructuring Practice with Addition of Genevieve Weiner
• Ingenia Therapeutics Nominated for Both the Prix Galien USA and the Inaugural Prix Galien Korea for Best Startup
• Banco Macro Announces Results for the Second Quarter of 2026